SPC275

Lorlatíníb eða lyfjafræðilega viðunandi salt þar af

  • Status:
    Veitt
  • Application date:
    19.8.2019
  • Application published:
    15.9.2019
  • Grant published:
    15.6.2022
  • Max expiry date:
    7.5.2034
  • Medicine name:
    Lorviqua
  • Medicine for children:
    No

Timeline

Today
19.8.2019Application
15.9.2019Publication
15.6.2022Registration
7.5.2034Expires

Marketing license

  • IS authorization number:
    EU/1/19/1355/001; EU/19/1355/002
  • Date:
    12.6.2019
  • Foreign authorization number:
    EU/1/19/1355
  • Date:
    6.5.2019

Owner

  • Name:
    Pfizer Inc.
  • Address:
    66 Hudson Boulevard East, New York, NY 10001-2192 US

Agent

  • Name:
    Árnason Faktor ehf.
  • Address:
    Guðríðarstíg 2-4, 113 Reykjavík

Patent

Upload documents